Vmn2r105 Inhibitors
The chemical class known as Vmn2r105 Inhibitors encompasses a diverse array of compounds that exert their inhibitory effects through distinct mechanisms. These inhibitors target various signaling pathways associated with Vmn2r105 activity, including the MAPK, PI3K/AKT, and TGF-β pathways. PD98059, LY294002, U0126, SB203580, Wortmannin, SP600125, Sorafenib, and Gefitinib inhibit key components of these pathways, such as MEK, PI3K, p38 MAPK, JNK, and EGFR, respectively. By blocking these signaling molecules, they disrupt downstream cellular responses mediated by Vmn2r105 activation. Additionally, Rapamycin, Axitinib, SB216763, and SB431542 exert indirect inhibitory effects by targeting mTOR, RTKs, GSK-3, and TGF-β type I receptor kinase, respectively. Through their actions on these targets, they can modulate cellular processes that intersect with Vmn2r105 signaling, contributing to overall inhibition. The chemical diversity within this class allows for the potential modulation of Vmn2r105-mediated cellular responses through multiple pathways, highlighting the complexity of inhibitory mechanisms targeting this protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which can hinder the MAPK signaling pathway, potentially impeding downstream effects of Vmn2r105 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits phosphatidylinositol 3-kinases (PI3K), affecting the PI3K/AKT signaling pathway. By disrupting this pathway, LY294002 may interfere with cellular processes influenced by Vmn2r105 signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 mitogen-activated protein kinase (MAPK), blocking the p38 MAPK signaling pathway. This inhibition can potentially modulate cellular responses regulated by Vmn2r105. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphatidylinositol 3-kinases (PI3K), similar to LY294002. Its interference with the PI3K/AKT pathway can disrupt downstream effects of Vmn2r105 activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits mitogen-activated protein kinase kinase (MEK), interfering with the MAPK signaling cascade. This disruption can potentially hinder cellular processes influenced by Vmn2r105. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), a component of the MAPK signaling pathway. By blocking JNK activity, SP600125 can potentially interfere with cellular responses mediated by Vmn2r105. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation. Its action on mTOR signaling can potentially modulate cellular processes downstream of Vmn2r105. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including Raf kinases involved in the MAPK signaling pathway. Its broad kinase inhibition can potentially disrupt cellular responses influenced by Vmn2r105. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR), which can affect the MAPK and PI3K/AKT signaling pathways. Its action on EGFR may indirectly modulate cellular processes mediated by Vmn2r105. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB216763 is a selective inhibitor of glycogen synthase kinase 3 (GSK-3), which can influence various signaling pathways. By inhibiting GSK-3, SB216763 may indirectly affect cellular responses regulated by Vmn2r105. | ||||||